Evaluating Tissue-Agnostic Approvals in Thoracic and Head and Neck Malignancies
Cancers · 06.03.2026 · 18 (5) · 856
DOI: 10.3390/cancers18050856 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 06.03.2026. Verfasst von Daniel Thomas Jones und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Sunrise Health GME Consortium, Las Vegas, NV 89148, USA. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Tissue-agnostic therapy has transformed oncology by enabling treatment selection based on molecular alterations rather than tumor origin. Since 2017, nine U.S. Food and Drug Administration approvals across six biomarker classes have defined this paradigm. Thoracic and head and neck (H&N) cancers have been underrepresented in the registrational evidence supporting these approvals. This review systematically evaluated biomarker representation, histologic distribution, and clinical applicability of tissue-agnostic therapies in thoracic and H&N malignancies.
Methods
A narrative systematic review was conducted using PubMed, ClinicalTrials.gov, and regulatory documents for all tissue-agnostic approvals between January 2017 and October 2025. Data were extracted from pivotal trials, including total enrollment, objective response rate (ORR), histologic distribution, and thoracic/H&N representation. Emerging biomarkers and resistance mechanisms were assessed from phase I–III studies and basket trials.
Results
Nine tissue-agnostic approvals encompassing six biomarkers were identified: MSI-H/dMMR, TMB-High, NTRK, RET, BRAF V600E, and HER2 (IHC 3+). Across pivotal datasets (3800 patients), thoracic and H&N cancers accounted for fewer than 8% (n = 290) of enrolled patients. Thoracic representation was dominated by non-small-cell lung cancer (NSCLC) in RET, NTRK, and HER2 programs (150 patients, 4%), while small-cell lung, mesothelioma, and thymic carcinomas contributed
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Sunrise Health GME Consortium, Las Vegas, NV 89148, USA.
- College of Osteopathic Medicine, Touro University Nevada, Las Vegas, NV 89014, USA.
- Department of Internal Medicine, Kirk Kerkorian School of Medicine at University of Nevada, Las Vegas (UNLV), Las Vegas, NV 89106, USA.
- Department of Internal Medicine, Interfaith Medical Center, Brooklyn, NY 11213, USA.
- Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University (OHSU), Portland, OR 97239, USA.
- Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
ORCID-Profile: Daniel Thomas Jones, Rajat Thawani, Mohamed Shanshal, Kyaw Zin Thein
Zitieren
APA
Jones, D. T., Nanda, R. K., Hussain, A. A., Hattin, R., Myat, Y. M., Thawani, R., Cetnar, J., Shanshal, M., Thein, K. Z., & Kummar, S. (2026). Evaluating Tissue-Agnostic Approvals in Thoracic and Head and Neck Malignancies. Cancers, 18(5), 856. https://doi.org/10.3390/cancers18050856
Vancouver
Jones DT, Nanda RK, Hussain AA, Hattin R, Myat YM, Thawani R, et al. Evaluating Tissue-Agnostic Approvals in Thoracic and Head and Neck Malignancies. Cancers. 2026;18(5):856. doi:10.3390/cancers18050856
BibTeX
@article{Jones2026,
author = {Jones, Daniel Thomas and Nanda, Rishi Kumar and Hussain, Abbas Ali and Hattin, Riccesha and Myat, Yin Mon and Thawani, Rajat and Cetnar, Jeremy and Shanshal, Mohamed and Thein, Kyaw Zin and Kummar, Shivaani},
title = {Evaluating Tissue-Agnostic Approvals in Thoracic and Head and Neck Malignancies},
journal = {Cancers},
year = {2026},
volume = {18},
number = {5},
pages = {856},
doi = {10.3390/cancers18050856}
}
EUVIMED